ArticleBMC public health2025
Trends and projections of Non-Hodgkin lymphoma burden (1990-2040): a global burden of disease 2021 analysis.
Article in BMC public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Critical flaws in: "Dupilumab and lymphoma risk among patients with asthma: a population-based cohort study".The European respiratory journal · 2026Article
- Article
- Burden of Middle-Aged and Elderly Patients With Non-Hodgkin Lymphoma From 1990 to 2021: A Systematic Analysis Based on the Global Burden of Disease 2021.Cancer medicine · 2026Article
- Global, regional, and national burden of lymphoma from 1990 to 2021: a comprehensive analysis based on the global burden of disease study 1990-2021.European journal of medical research · 2026Article
- Using period analysis to timely provide serial data on long-term survival for patients with hematological malignancies from Taizhou, Eastern China.Frontiers in oncology · 2026Article
- Identifying a Novel BCL2L1-Targeting Peptide from Porcine Placenta for Lymphoma Therapy.ACS omega · 2025Article
- Article
- Global, regional, and national disease burden of lymphoma and leukemia attributable to high body mass index: from 1990 to 2021.Frontiers in nutrition · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNon-Hodgkin lymphoma (NHL) is a common type of lymphoma. These vary geographically and within specific areas. A comprehensive and precise assessment of the global burden of NHL is important for the forward-looking planning and implementation of health policies.
methodsThis study used data from the 2021 Global Disease Burden (GBD) study. We examined trends in disease burden in non-Hodgkin lymphoma patients using indicators including the incidence, prevalence, deaths, and disability-adjusted years of life (DALY), as well as the age-standardized incidence rate (ASIR), age-standardized prevalence rate (ASPR), age-standardized mortality rate (ASMR), and age-standardized DALY rate (ASDR). Temporal trends in NHL risk factors from 1990 to 2021 were analyzed. Joinpoint regression was used to determine the average annual percentage change (AAPC) in the age-standardized rate. The Bayesian age-period-cohort (BAPC) model was used to predict the age-standardized mortality and DALY rates by 2040.
resultsIn 2021, the NHL's global age-standardized incidence rate (ASIR) was 7.1 per 100,000 people. From 1999 to 2021, there was a downward trend in ASMR and ASDR of NHL (AAPC = -0.6 and -0.8, respectively), but ASIR and ASPR of NHL showed an upward trend (AAPC = 0.3 and 1.2, respectively). According to the socio-demographic index (SDI), the ASIP and ASPR of NHL were higher in regions and countries with higher SDI. The study also found an increase in ASMR and ASDR associated with high body mass index (BMI) in NHL. In addition, it is predicted that the global ASIR and ASPR will continue to show a slow upward trend in the next 2040, whereas ASMR and ASDR will gradually decline.
conclusionNon-Hodgkin lymphoma (NHL) remains a formidable public health challenge; however, different regions and socioeconomic statuses have different trends. A more aggressive, individualized intervention strategy is needed based on dynamic changes. Simultaneously, close international collaboration is essential to advance improvements in NHL management, including strengthening diagnostic and treatment strategies, strengthening healthcare infrastructure, expanding access to high-quality healthcare services, and strengthening public health education.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.